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DISCUSSION
Though hypercalcemia is commonly seen in adult T cell 
lymphomas/leukemia and solid tumors via excess 
production of PTHrP, less than 10% of patients with non 
Hodgkins B-cell lymphomas develop hypercalcemia.2  The 
hypercalcemia seen in B cell lymphomas is usually due to 
non PTHrP related mechanisms. There are various 
explanations of the pathophysiology for hypercalcemia in 
hematologic malignancies. Most of the case studies that 
have reported B-cell lymphomas with hypercalcemia 
secondary to PTHrP hypersecretion are high grade 
lymphomas. Our patient’s case supports these findings, as 
he too had a Richter's transformation on bone marrow 
biopsy.1 Correlation between the concentration of the 
protein and the degree of hypercalcemia suggests a 
causal relationship. Numerous case reports have shown 
that hypercalcemia in B cell lymphoma is a poor prognostic 
factor. In Majmudar's article, of the eight patients he 
reported, median survival time from developing 
hypercalcemia was nine months.3
KEY POINTS
The mechanisms of hypercalcemia in hematologic 
malignancies are multifactorial and yet to be fully 
understood. However, it is important to evaluate the cause 
and promptly treat the hypercalcemia. It is imperative to 
determine calcium levels given that it is a prognostic 
indicator and of clinical significance. PTHrP mediated 
hypercalcemia is rare in B cell lymphomas, but has been 
reported in high grade and transformed disease and 
should be considered in the evaluation of hypercalcemia 
in this subset of patients. 
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INTRODUCTION
Hypercalcemia is commonly associated with solid tumor 
malignancies, but less often with hematologic malignancies. 
When present in hematologic malignancies, hypercalcemia 
is often secondary to overproduction of Vitamin D from the 
tumor cells. Very few cases with parathyroid hormone 
related peptide (PTHrP) induced hypercalcemia in B-cell 
lymphomas have been reported. Here we present a 44 year 
old male with a history of chronic lymphoctic leukemia 
who presented with hypercalcemia and an elevated PTHrP, 
found to have a transformation to Diffuse Large B-cell 
Lymphoma (DLBCL) .
CASE PRESENTATION
A 44 year old male with chronic lymphocytic leukemia 
(CLL) status post four cycles of rituximab, cyclophos-
phamide, vincristine and prednisone and currently 
undergoing treatment with ibrutinib presented with two 
weeks of decreased appetite, fatigue, weakness, altered 
mental status.  Physical exam was only significant for mild 
cervical lymphadenopathy. Labs revealed hypercalcemia 
at 18.1 mg/dL, compared to 12 mg/dL one month prior to 
admission. Work up of hypercalcemia revealed normal 
intact PTH and Vitamin D levels, and elevated PTHrP at 57 
pmol/L.  Upon further investigation, including a bone 
marrow biopsy, it was determined that the CLL had 
transformed to a more aggressive subtype, diffuse large 
B-cell Lymphoma. He did not complain of any abdominal 
pain, but did complain of diffuse bone pain. CT of the 
chest, abdomen, and pelvis showed adenopathy 
throughout with some mild splenomegaly. The patient's 
hypercalcemia was treated with fluids, calcitriol, and 
pamidronate with improvement in symptoms and 
normalization of calcium levels. His DLBCL was treated 
with a cycle of cyclophosphamide, doxorubicin, vincristine, 
and prednisone (CHOP). However, his neutrophil count 
did not recover as expected and his calcium began to 
increase again two weeks after initial treatment. A repeat 
bone marrow biopsy was consistent with refractory B-cell 
lymphoma. His hypercalcemia was again treated with 
fluids and re-dosing of pamidronate, which stabilized his 
calcium between 11 and 12 mg/dL, but did not normalize 
it. He began experiencing fatigue and bone pain again. He 
was started on dexamethasone 6 mg every 6 hours which 
returned his calcium to normal range and relieved his 
symptoms. His calcium has remained stable since, and he 
is to undergo therapy with bendamustine, ofatumumab, 
carboplatin, and etoposide.
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